ACURA PHARMACEUTICALS Enters Material Agreement, Completes Asset Deal
| Field | Detail |
|---|---|
| Company | Acura Pharmaceuticals, Inc |
| Form Type | 8-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition-disposition, financial-obligation
TL;DR
ACURA PHARMACEUTICALS just closed an asset deal and signed a big agreement - could be a game-changer!
AI Summary
On July 18, 2025, ACURA PHARMACEUTICALS, INC. entered into a material definitive agreement related to the completion of an acquisition or disposition of assets. This also resulted in the creation of a direct financial obligation for the registrant. The company is incorporated in New York and its fiscal year ends on December 31.
Why It Matters
This filing indicates a significant corporate action, potentially involving the acquisition or sale of assets, which could impact ACURA PHARMACEUTICALS' future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements and asset acquisitions/dispositions inherently carry financial and operational risks that can impact the company's stability.
Key Players & Entities
- ACURA PHARMACEUTICALS, INC. (company) — Registrant
- July 18, 2025 (date) — Date of earliest event reported
- New York (jurisdiction) — State of incorporation
- 1-10113 (commission_file_number) — SEC File Number
- 11-0853640 (ein) — I.R.S. Employer Identification Number
FAQ
What specific assets were involved in the acquisition or disposition?
The filing does not specify the exact assets involved in the acquisition or disposition.
What is the nature of the material definitive agreement entered into?
The filing indicates the entry into a material definitive agreement but does not detail its specific terms or purpose.
What is the direct financial obligation created for the registrant?
The filing states a direct financial obligation was created but does not provide details on its amount or terms.
When was ACURA PHARMACEUTICALS, INC. incorporated?
ACURA PHARMACEUTICALS, INC. was incorporated in New York.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding ACURA PHARMACEUTICALS, INC.